TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01773395
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant.
Study: NCT02016066
Drug: CR6261
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
Study: NCT02016066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single 2-hour intravenous infusion
Study: NCT01558687
Drug: Drug (including placebo)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide.
Study: NCT03735979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo solution
Study: NCT02802345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00634413
Drug: Theophylline - ADC4022
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled theophylline (ADC4022) administered twice daily for 28 days
Study: NCT00634413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled matching placebo administered twice daily for 28 days
Study: NCT01211691
Drug: KB004, Monoclonal Antibody
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01817972
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg tablets
Study: NCT00022516
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/day orally continuously for 1 year
Study: NCT00022516
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 mg twice/day orally days 1 and 2 of every week for 1 year
Study: NCT03237689
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Low dose hydrocortisone (10mg)
Study: NCT03237689
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules of starch 1500 powder
Study: NCT02366819
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02366819
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01194986
Drug: AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002700
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002700
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002700
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002700
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002700
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002700
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002700
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00202540
Drug: S18986
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247830
Drug: Urea cream
Normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
Study: NCT03239223
Drug: ABI-1968
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
Study: NCT02567695
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
Study: NCT00499265
Drug: Serine Proteinase Inhibitor WX-671
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily
Study: NCT00049764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04856761
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
Study: NCT01665638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
Study: NCT00002828
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01739595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule taken one time daily for 3 months
Study: NCT02291341
Drug: Cymbalta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg capsule of Eli Lilly and Company
Study: NCT02024581
Drug: 10% East Indian sandalwood oil cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
Study: NCT02024581
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
Study: NCT05828940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, over-encapuslated
Study: NCT00003018
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
Study: NCT00003018
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
Study: NCT01287117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Study: NCT01786018
Drug: Immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
Study: NCT01786018
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
Study: NCT01186432
Drug: PDS 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02951598
Drug: Florbetapir F 18 PET Scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
Study: NCT02942498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01954290
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
Study: NCT02819596
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00984789
Drug: Norelgestromin/Ethinylestradiol (EVRA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6mg ethinylestradiol and 6mg norelgestromin
Study: NCT01878565
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
Study: NCT01451515
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.
Study: NCT01451515
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT01451515
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, IM or IT.
Study: NCT01451515
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO.
Study: NCT01451515
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IT.
Study: NCT03623750
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
Study: NCT02941731
Drug: HIP1403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 6mg/mL
Study: NCT02941731
Drug: HGP0919
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir phosphate 6mg/mL
Study: NCT04819828
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
Study: NCT01023282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Study: NCT00644579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01439958
Drug: Inhalation
Normalized name: INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily inhalation for a maximum of three years.
Study: NCT01217775
Drug: PH80
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PH80 intranasal spray 800 nanograms
Study: NCT01217775
Drug: Placebo intranasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal spray
Study: NCT00671151
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 100 mg bid for 3 months
Study: NCT00091793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given at day 1, month 6, month 12 and month 18
Study: NCT00002516
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006812
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03271489
Drug: E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT00080327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0mg, Once daily, 6 weeks.
Study: NCT02557503
Drug: Oxaliplatin and fluorouracil
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
Study: NCT00195351
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Study: NCT02634515
Drug: Julphar Insulin R (soluble human insulin, biosimilar)
Normalized name: insulin, regular, human Injectable Solution [Novolin R]
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational insulin, Julphar Insulin R (soluble human insulin)
Study: NCT02634515
Drug: Huminsulin® Normal (soluble human insulin, reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: marketed product, Huminsulin® Normal (soluble human insulin
Study: NCT03797443
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid.
Study: NCT03240081
Drug: 50mcg estradiol cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of study drug nightly applied to vulvar vestibule
Study: NCT03240081
Drug: 100mcg estradiol cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of study drug nightly
Study: NCT03867253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00761540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
Study: NCT00761540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
Study: NCT00761540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
Study: NCT00729430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken orally once per day for 6 months
Study: NCT02285010
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
Study: NCT04795180
Drug: Irrigations trough the efferent limb of loop ileostomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
Study: NCT00152256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet, oral Daily for 6 months
Study: NCT01870466
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin qd for 7 days
Study: NCT01870466
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin qd for 7 days
Study: NCT01450137
Drug: Placebo + Glucocorticoids (GCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 4 weeks until week 52.
Study: NCT01275638
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
Study: NCT03968146
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
Study: NCT03968146
Drug: additional Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
Study: NCT03968146
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
Study: NCT03968146
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
Study: NCT02936895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 days
Study: NCT02838030
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 gr per day
Study: NCT01208181
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally once daily for 6 weeks.
Study: NCT01208181
Drug: Etoricoxib 90 mg
Normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally once daily for 6 weeks.
Study: NCT01208181
Drug: Placebo to Etoricoxib 60 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally once daily for 6 weeks.
Study: NCT01208181
Drug: Placebo to Etoricoxib 90 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally once daily for 6 weeks
Study: NCT00982722
Drug: cholecalciferol and calcium carbonate
Normalized name: calcium carbonate / cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Study: NCT00942708
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID
Study: NCT00104507
Drug: APD356
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004287
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study: NCT03556696
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
Study: NCT03163238
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
Study: NCT02704429
Drug: PRN1008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks.
Study: NCT00104104
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
Study: NCT00630032
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m² every 3 weeks
Study: NCT00630032
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m² every 3 weeks
Study: NCT00870493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch tablet, 300 mg/day
Study: NCT04713319
Drug: Panavital
Normalized name: NIACINAMIDE 2 g in 100 g / ADENOSINE 0.04 g in 100 g TOPICAL CREAM [TAEYANGSOO Plavital RxCream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
Study: NCT06456723
Drug: [18F]-FET-βAG-TOCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA) - maximum injected dose of 370MBq - followed PET/CT imaging.